Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 4
1(25.0%)
4Total
Phase 2(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01977417Phase 2Terminated

Inflammation Inhibition in Prediabetic Humans

Role: lead

NCT01983462Phase 2Terminated

Vascular Dysfunction in Human Obesity Hypertension

Role: lead

NCT03611699Phase 4Completed

Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients

Role: lead

NCT01775865Phase 2Completed

Targeting Inflammation to Treat Cardiovascular Aging

Role: lead

All 4 trials loaded